

Publication of Kazuo Umezawa from 2010 to 2011. Articles in Japanese are removed, so there are gaps in number.

307. M. Morioka, A. Kamizono, H. Takikawa, A. Mori, H. Ueno, S. Kadowaki, Y. Nakao, K. Kato and K. Umezawa: Design, synthesis, and biological evaluation of novel estradiol-bisphosphonate conjugates as bone-specific estrogens. *Bioorg. Med. Chem.* 11:1143-1148, 2010.

308. M. Kawakami, A. Hirayama, K. Tsuchiya, H. Ohgawara, M. Nakamura, and K. Umezawa: Promotion of β -cell differentiation by the alkaloid conophylline in porcine pancreatic endocrine cells. *Biomedicine & Pharmacotherapy* 64: 226–231, 2010.

309. M. Takeuchi, S. Kimura, J. Kuroda, E. Ashihara, M. Kawatani, H. Osada, K. Umezawa, E. Yasui, M. Imoto, T. Tsuruo, A. Yokota, R. Tanaka, R. Nagao, T. Nakahata, Y. Fujiyama and T. Maekawa: Glyoxalase-I is a novel target against Bcr-Abl⁺ leukemic cells acquiring stem-like characteristics in hypoxic environment. *Cell Death Diff.* 2010: 1-10, 2010.

310. K. Kodaira, E. Kikuchi, M. Kosugi, Y. Horiguchi, K. Matsumoto, K. Kanai, E. Suzuki, A. Miyajima, K. Nakagawa, M. Tachibana, K. Umezawa and M. Oya: Potent cytotoxic effect of a novel nuclear factor-kappa B inhibitor on human bladder cancer cells producing various cytokines. *Urology* 75: 805-812, 2010.

311. M. Murohashi, K. Hinohara, M. Kuroda, T. Isagawa, S. Tsuji, S. Kobayashi, K. Umezawa, A. Tojo, H. Aburatani and N. Gotoh: Gene set enrichment analysis provides insight into novel signaling pathways in breast cancer stem cells. *British J. Cancer* 102: 206-212, 2010.

312. R. Dror, M. Lederman, K. Umezawa, V. Barak, J. Pe'er and I. Chowers: Characterizing the involvement of the nuclear factor-kappa B (NF κ B) transcription factor in uveal melanoma. *Investigative Ophthalmology & Visual Science* 58: 1811-1816, 2010.

313. D. Iwata, N. Kitaichi, A. Ebihara, K. Iwabuchi, K. Yoshida, K. Namba, M. Ozaki, S. Ohno, K. Umezawa, K. Yamashita, S. Todo, S. Ishida and K. Onoé: Nuclear factor- κ B inhibitor, dehydroxy methyl epoxyquinomicin ameliorates experimental

autoimmune uveoretinitis (EAU) in mice. *Investigative Ophthalmology & Visual Science* 51: 2077-2084, 2010.

314. C. Shimada, Y. Ninomiya, E. Suzuki and K. Umezawa: Efficient cellular uptake of the novel NF- κ B inhibitor (-)-DHMEQ and irreversible inhibition of NF- κ B in neoplastic cells. *Oncology Research*, 18: 529-535, 2010.

315. A. Miyake, T. Ishida, M. Yamagishi, T. Hara, K. Umezawa, T. Watanabe and R. Horie: Inhibition of active HIV-1 replication by NF- κ B inhibitor DHMEQ. *Microbes and Infection* 12: 400-408, 2010.

316. A. Hamasaka, N. Yoshioka, R. Abe, S. Kishino, K. Umezawa, M. Ozaki, S. Todo and H. Shimizu: Topical application of DHMEQ improves allergic inflammation via NF- κ B inhibition. *Journal of Allergy and Clinical Immunology* 126: 400-403, 2010.

317. M. Hamada, T. Higashi, M. Shoji, K. Umezawa and T. Sugai: Lipase-catalyzed enantio- and regioselective transformation of 3-epi-shikimic acid derivatives as the key step for the entry of polyoxygenated carbacycles. *Journal of Molecular Catalysis B: Enzymic* 67: 78-84, 2010.

318. M. Hamada, Y. Niitsu, C. Hiraoka, I. Kozawa, T. Higashi, M. Shoji, K. Umezawa, T. Sugai: Chemoenzymatic synthesis of (2S,3S,4S)-form, the physiologically active stereoisomer of dehydroxymethylepoxyquinomicin (DHMEQ), a potent inhibitor on NF- κ B. *Tetrahedron* 66:7083-7087, 2010.

319. N. Miyanishi, Y. Suzuki, S. Simizu, Y. Kuwabara, K. Banno and K. Umezawa: Involvement of autocrine CXCL12/CXCR4 system in the regulation of ovarian carcinoma cell invasion. *Biochem. Biophys. Res. Commun.* 403: 154-159, 2010.

320. V. Cardile, G. Frasca, M. Libra, S. Caggia, K. Umezawa, A. Panico and G. Malaponte: Dehydroxymethylepoxyquinomicin inhibits expression and production of inflammatory mediators in interleukin-1 β -induced human chondrocytes. *Cellular Physiology and Biochemistry* 25: 543-550, 2010.

321. T. Takahashi, S. Matsumoto, M. Matsushita, H. Kamachi, Y. Tsuruga, H. Kasai, M. Watanabe, M. Ozaki, H. Furukawa, K. Umezawa and S. Todo. Donor pretreatment

with DHMEQ improves islet transplantation. *Journal of Surgical Research* 163: e23-34, 2010.

322. E. Suzuki, T. R. Daniels, G. Helguera, M. L. Penichet, K. Umezawa and B. Bonavida: Inhibition of NF- κ B and Akt pathways by an antibody-avidin fusion protein sensitizes malignant B-cells to cisplatin-induced apoptosis. *International J. Oncology* 36: 1299-1307, 2010.

323. T. Saitoh, C. Shimada, M. Takeiri, M. Shiino, S. Ohba, R. Obata, Y. Ishikawa, K. Umezawa and S. Nishiyama: A novel NF- κ B inhibitor based on the amino-epoxyquinol core of DHMEQ. *Bioorg. Med. Chem. Lett.* 20: 5638-5642, 2010.

324. V. Cardile, M. Libra, S. Caggia, G. Frasca, K. Umezawa, F. Stivala, M. C. Mazzarino, Y. Bevelacqua, M. Coco and G. Malaponte: Dehydroxyquinomicin, a novel NF-kappa B inhibitor, prevents inflammatory injury induced by IFN- γ and histamine in keratinocytes NCTC 2544. *Cellular and Experimental Pharmacology and Physiology* 37: 679-683, 2010.

325. K. Shinoda, K. Nakagawa, T. Kosaka, N. Tanaka, T. Maeda, H. Kono, R. Mizuno, E. Kikuchi, A. Miyajima, K. Umezawa, M. Oya: Regulation of human dendritic cells by a novel specific nuclear factor- κ B inhibitor, dehydroxymethylepoxyquinomicin. *Human Immunology* 71: 763-770, 2010.

326. L. Levati, F. Ruffini, A. Muzi, K. Umezawa, G. Graziani, S. D'Atri, P. M. Lacial: Placenta growth factor induces melanoma resistance to temozolomide through a mechanism that involves the activation of the transcription factor NF- κ B. *International J. Oncol.* 38: 241-247, 2011.

327. K. Mino, M. Ozaki, K. Nakanishi, S. Haga, M. Sato, M. Kina, M. Takahashi, N. Takahashi, A. Kataoka, K. Yanagihara, T. Ochiya, T. Kamiyama, K. Umezawa and S. Todo: Inhibition of nuclear factor-kappaB suppresses peritoneal dissemination of gastric cancer by blocking cancer cell adhesion. *Cancer Science* 102: 1052-1058, 2011.

328. K. Kobayashi, K. Umezawa and M. Yasui: Apoptosis in mouse amniotic epithelium is induced by activated macrophages through the TNF receptor type 1/TNF pathway. *Biology of Reproduction* 84: 248-254, 2011.

330. Y. Niitsu, M. Hakamata, Y. Goto, T. Higashi, M. Shoji, T. Sugai and K. Umezawa: Chemoenzymatic synthesis of (2*R*,3*R*,4*R*)-dehydroxymethylepoxyquinomicin (DHMEQ), a new activator of antioxidant transcription factor Nrf2. *Org. Biomol. Chem.* 9: 4635-4641, 2011.
331. K. Umezawa: Possible role of peritoneal NF- κ B in peripheral inflammation and cancer: Lessons from the inhibitor DHMEQ. *Biomedicine & Pharmacotherapy* 65: 252-259, 2011.
332. H. Hosoi, N. Kawai, H. Hagiwara, T. Suzuki, A. Nakazaki, K. Takao, K. Umezawa and S. Kobayashi: Synthesis and determination of the relative structure of akaterpin, a potent inhibitor of PI-PLC. *Tetrahedron Letters* 52: 4961-4964, 2011.
333. V. Rapozzi, K. Umezawa and L. E. Xodo: Role of NF- κ B/Snail/RKIP loop in the response of tumor cells to photodynamic therapy. *Lasers in Surgery and Medicine* 43: 575–585, 2011.
334. M. Isshiki, K. Umezawa and H. Tamura: Coffee induces breast cancer resistance protein expression in Caco-2 cells. *Biol. Pharm. Bull.* 34: 1624-1627, 2011.
335. E. Suzuki, S. Yamashita and K. Umezawa: Role of NF- κ B in thyroid cancer. In A. Carpi and J. L. Mechanick eds. "Thyroid Cancer, from Emergent Biotechnologies to Clinical Practice Guidelines" CRC Press, pp 319-327, 2011.
336. T. Saitoh, M. Takeiri, Y. Gotoh, Y. Ishikawa, K. Umezawa and S. Nishiyama: Design and synthesis of biotinylated DHMEQ for direct identification of its target NF- κ B components. *Bioorganic & Medicinal Chemistry Letters* 21: 6293–6296, 2011.
337. K. Tsumura, A. Suzuki, T. Tsuzuki, H. Kaneko, S. Matsumura, M. Imoto, K. Umezawa, D. Takahashi and K. Toshima: Molecular design, chemical synthesis, and biological evaluation of agents that selectively photo-degrade the transcription factor estrogen receptor- α . *Org. Biomol. Chem.* 9: 6357-6366, 2011.
338. M. Takeiri, M. Tachibana, A. Kaneda, A. Ito, Y. Ishikawa, S. Nishiyama, R. Goto, K. Yamashita, S. Shibasaki, G. Hirokata, M. Ozaki, S. Todo and K. Umezawa: Inhibition

of macrophage activation and suppression of graft rejection by DTCM-glutarimide, a novel piperidine derived from the antibiotic 9-methylstreptimidone. *Inflammation Research* 60: 879-888, 2011.

339. T. Kubota and K. Umezawa: Suppression of erosive arthritis by NF- κ B Inhibitors. *Current Rheumatology Reviews* 7: 275-281, 2011.